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Pulmonary hypertension (PH) often complicates the course of patients with advanced lung disease, and it is associated with a worse prognosis. Per the recent classification of pulmonary hypertensive disorders, PH due to lung disease is considered as a separate category within a group of disorders that was previously referred to as "secondary" PH. Among the lung diseases associated with PH, the incidence and clinical course of PH is best known for patients with COPD. Per studies in patients with COPD and other lung disorders, it is evident that the pathophysiology and treatment of these disorders is generally distinct from that of pulmonary arterial hypertensive disorders. Changes in the pulmonary vasculature that accompany elevations in pulmonary vascular pressure are generally referred to as pulmonary vascular remodeling. Chronic hypoxia is well known to cause pulmonary vascular remodeling and PH, and it is the major mechanism implicated for the development of PH in patients with lung disease. Other mediators have also been implicated in the pathogenesis of PH in animal models and patients with PH, including patients with pulmonary diseases. General features of pulmonary vascular remodeling are discussed with particular emphasis on those changes that have been described in patients with lung diseases. Recent discoveries in these areas are also reviewed, and findings in pulmonary arterial hypertensive diseases are contrasted with those found in patients with PH due to lung diseases. Some of these discoveries have already led to new treatment strategies for patients with the most severe forms of PH. PH due to lung diseases shares some common pathophysiologic features with pulmonary arterial hypertension. Therefore, it is likely that these discoveries and new treatments will also be extended to benefit patients with PH due to lung disease. Pulmonary hypertension (PH), defined as a mean pulmonary artery (PA) pressure above 20 mm Hg, often complicates the course of patients with advanced lung disease and portends a worse prognosis [1-3,4•]. Cor pulmonale was initially a term that referred to heart enlargement due to intrinsic parenchymal lung disease. Subsequently, the expression cor pulmonale became more inclusive and precise. It now refers to cardiomegaly that is predominantly due to right heart enlargement resulting from either intrinsic pulmonary diseases, including disorders of the pulmonary vessels or abnormal respiratory function [3] . Decompensated cor pulmonale is signaled by the development of edema and corresponds to the development of right heart failure with corresponding elevation in right heart pressures and systemic venous pressure. The ensuing discussion will include a brief update on the current classification of pulmonary disorders and the general features of PH associated with lung diseases; this is followed by a review of the role of chronic hypoxia and other mediators in pulmonary vascular remodeling in patients with PH and lung disease. These features are contrasted with the findings in patients with severe PH due to pulmonary arterial hypertension.
Classification and diagnosis
The recent 1998 classification of PH is shown in Table 1 [5•]. PH due to lung disorders is separated particularly from pulmonary arterial hypertensive diseases, such as primary PH (PPH). These latter patients often have more severe PH, and they are currently treated differently than patients with lung disease and PH. It should be noted that the collagen vascular and Scleroderma-like disorders are included under pulmonary arterial hypertension disorders since these patients can develop a severe pulmonary vasculopathy independent of pulmonary fibrosis. Diagnosis of cor pulmonale can be made by noninvasive tests, specifically chest x-ray, electrocardiogram, CT scan of the chest, and echocardiogram [4•,6-8]. Echocardiography increases the sensitivity of noninvasive evaluation in these patients but may still be limited due to technical considerations, particularly in patients with COPD. Therefore, right heart catheterization may be necessary to determine the degree of PH and right ventricular dysfunction. When PH is found in patients with lung disease, it is still necessary to rule out other common etiologies that may be causative, such as left ventricular dysfunction (pulmonary venous hypertension), or pulmonary thromboembolic disease. Treatment for patients with lung disorders has largely been limited to oxygen and disease-specific treatment. An increased understanding of the pathophysiology of PH in these diseases will hopefully lead to more treatment options for these patients in the future.
Characteristics of pulmonary hypertension due to lung diseases
The degree of PH seen in patients with lung disorders is generally reported to be mild to moderate. However, symptoms and morbidity can be compounded by the presence of cor pulmonale [9] . PH in these disorders usually parallels the degree of lung disease and particularly the degree of hypoxemia [10, 11] . Therefore, similar to the course of patients with various forms of lung disease, the degree of PH can be relatively stable over years. This is in contrast to what is described in patients with pulmonary arterial hypertension disorders who often have severe PH at diagnosis and relentless progression to right heart failure. There are uncommon patients with lung disease who also have severe PH [12] . It is not known whether these uncommon patients have other contributing genetic or physiologic factors that make their PH more severe. It is possible that those patients with the most severe form of PH in association with lung disease may have a coincidental genetic predisposition towards PPH. Further studies will need to be done to determine whether the genetic abnormalities described in patients with familial and sporadic PPH are seen in these patients as well [13-15•,16] .
Pulmonary hypertension in patients with COPD
The prevalence of cor pulmonale in certain lungs disorders has been estimated by data from moderate size, single center studies, and the best data is available for patients with chronic obstructive pulmonary disease (COPD). Resting PA pressure in patients with COPD and other lung disorders has been reported to correlate best with PaO 2 rather than the degree of airways obstruction [10, 11] . Patients with advanced pulmonary fibrosis often have PH, and it can be moderate to severe [9, 17] . Weitzenblum et al.
[18] reported a cohort of 93 patients with COPD, and PH was present in 32 of them; the degree of PH was mild to moderate (PA pressure = 25.8 ± 5.6 mm Hg) with normal RVEDP (5.2 ± 3.4 mm Hg) and Cardiac Index (3.8 ± 1.1 L/min m 2 ). Forced expiratory volume in 1 second (FEV 1 ) (1.2 ± 0.4 vs 1.42 ± 0.4, L) and PaO 2 (62.7 ± 8.8 vs 67.0 ± 7.4 mm Hg) were lower for the group with PH than for the group without PH. All patients were followed for at least 5 years, and there was a modest increase in PA pressure overall with no significant change in resting right heart pressures or cardiac output. However, a subset of patients showed a significant increase in PA pressure (Ն 5 mm Hg) that best correlated with a decline in PaO 2 . PaO 2 did not change significantly in those patients whose PA pressure did not increase [18] . Naeije [19] reported a consecutive case series of 74 patients with severe COPD who had been admitted with respiratory failure and had right heart catheterization studies performed on room air several days after therapy [19] . It is known that exacerbations of COPD will aggravate PH, and it may take many days to return to baseline hemodynamics. Nonetheless, this study again demonstrated an inverse relation between PA pressure and PaO 2 ; mean PA pressure for this group was higher, 35 mm Hg (range 15 to 78 mm Hg) and mean pulmonary vascular resistance (PVR) was 660 dyne/sec/cm 5 /m 2 (range 231 to 1377 dyne/sec/cm 5 /m 2 ). Mean RA pressure was normal at 3 mm Hg, and cardiac output was also normal (3.8 L/min/m 2 ). Whereas the PA pressure values were higher in this group of patients with severe COPD, systolic PA pressure only achieved systemic levels in one patient in contrast with the PH levels that are commonly seen in patients with advanced pulmonary arterial hypertension [19] .
Prior studies indicated that isolated nocturnal oxygen desaturation was associated with PH in patients with COPD independent of daytime hypoxemia [20] . However, subsequent larger studies failed to show any difference in PA pressure between COPD patients with or without nocturnal desaturation [21•]. Nevertheless, certain animal models have shown increases in PA pressure and hematocrit with intermittent, hypercapnic hypoxia [22] . Whether this finding is relevant to other patient groups remains to be determined.
Pulmonary vascular remodeling
General features of pulmonary vascular remodeling are listed in Table 2 . Additionally, findings common to patients with pulmonary arterial hypertension are contrasted with those seen in patients with PH and lung disorders. Vascular remodeling involves changes in all three levels of the vessel wall: the adventitia, media, and intima (luminal side). Therefore, at the cellular level, the process will involve the fibroblasts, smooth muscle cells, and endothelial cells. The intermediate cell and the pericyte are cells present in the small, partially muscularized and unmuscularized vessels, respectively; these cells are prominent in the remodeling process and can be stimulated to differentiate and proliferate under various normal and abnormal conditions. Pathologic studies in patients with PH and lung disorders have reported prominent medial smooth muscle hypertrophy, distal smooth muscle proliferation with neomuscularization of small pulmonary vessels, and mild intimal changes (Fig. 1) . Longitudinal bundles of smooth muscle cells have been described in all three layers of the vessel [23] . Patients with pulmonary arterial hypertension and severe PH also have these changes. Additionally, studies in these latter patients have also disclosed significant adventitial changes with deposition of collagen and extracellular matrix, marked intimal proliferation, unique endothelial cell changes, and plexogenic lesions [24] [25] [26] .
Interestingly, the animal models of chronic hypoxic PH have shown reversibility of the pathologic changes with return to normoxia. Acute hypoxic pulmonary vasoconstriction in patients is relieved with administration of oxygen. Patients with high altitude, ambient hypoxiaassociated PH are known to improve their condition as they acclimate to sea level due to relief of acute vasoconstriction, likely regression of remodeling changes and decrease in polycythemia. It is less clear whether the pulmonary vascular remodeling changes associated with chronic hypoxia and lung disease are reversible simply with oxygen therapy. The two large clinical trials of longterm oxygen therapy (LTOT) in patients with COPD were reported in the early 1980s and showed an increased survival with the use of oxygen for more than 15 hours per day in hypoxemic patients. One study reported the mitigation of the progression of PH with the use of 15 or more hours of oxygen as compared with no oxygen therapy [27] . The other study reported a mild decrease in PVR with near continuous oxygen therapy 
Chronic hypoxia and pulmonary vascular remodeling
Chronic hypoxia is implicated as the most important stimulus for vascular remodeling in patients with PH and lung diseases. Indeed, the changes described above in patients with cor pulmonale are the key changes that have been seen in animal models of chronic hypoxia (Fig. 1) [30-32 ]. Other mediators have also been implicated in the development of PH based on human and animal investigations. Certain in vitro studies with human PA cells and animal models suggest that ion current channnels, endothelin, nitric oxide (NO), prostacyclin, angiotensin II, serotonin, and elastase all are involved with the remodeling process triggered by chronic hypoxia [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] . Hypoxia is well known to cause vasoconstriction, which in turn causes increased pressure, wall stress, and increased shear forces; these mechanical factors have been described to initiate a cascade of mediators and cellular changes that may also contribute to the remodeling process [32] . Some investigators have also described decreased arterial vessel density in the rat model of chronic hypoxic PH, whereas others have questioned this finding [30, 32] . In patients with lung disease, decreased vessel density is reported to occur due to the destruction and fibrosis that accompanies these pro- This change occurs early (within 2 days) and can induce pulmonary vasoconstriction; this process is fully reversible with return to normoxia. A more "active" role for hypoxia has been demonstrated in other studies that have reported an increase in the release of various mitogens in response to hypoxia. Human smooth muscle cells have been reported to proliferate and produce increased interleukin-1␣ [49] in response to hypoxia and porcine PA smooth muscle cells have also shown increased production of growth factors [50] . Medial thickening with marked smooth muscle hypertrophy is seen in the rat model of chronic hypoxia [30] . Additionally, new smooth muscles cells can be seen within 2 days in the distal arteries that are normally unmuscularized or partially muscularized. This is due to proliferation and hypertrophy of the pericytes and intermediate cells that are normally present in these vessels [30, 31] . This is accompanied by an increase in the thickness of the elastic laminae and in connective tissue components with an increase in the thickness of the adventitial layer. Increased elastin and collagen synthesis has been demonstrated in the pulmonary arteries from chronically hypoxic rats [51] . These latter changes are thought to occur in order to strengthen the vessel wall in the face of increased pressure, and these vessels have indeed been shown to be less distensible [51] .
Certain select compounds have been implicated in the pathogenesis of chronic hypoxic PH. Endothelin-1 is a potent vasoconstrictor and a co-mitogen that has been shown to have an important role in pulmonary vascular remodeling [17, [53] [54] [55] [56] . Endothelin-1 binds to endothelin A and B receptors; the endothelin A receptors are felt to be more central to the pulmonary vascular constriction and remodeling process initiated by endothelin-1 [40] . Although, endothelin B2 receptors on smooth muscle cells also regulate vasoconstriction whereas endothelin B1 receptors on endothelial cells cause vasodilation when bound by endothelin-1. Increased expression of endothelin-1 mRNA has been reported in the lungs of the chronically hypoxic rat [57] . Furthermore, endothelial cells have been shown to produce increased endothelin-1 and PDGF in response to hypoxia [38] . Angiotensin converting enzyme (ACE) is present in the endothelium of small and elastic arteries and Angiotensin II binding is increased in the chronically hypoxic rat [44, 45] . Therefore, Angiotensin II may contribute to the smooth muscle hypertrophy and proliferation seen in chronic hypoxia. Increased serine elastase has also been demonstrated in the vessels of chronically hypoxic rats and elastase inhibitors have been shown to mitigate the development of chronic hypoxic PH [41, 52] .
Mediators of pulmonary vascular remodeling Human studies
Investigators have extended the study for certain mediators of pulmonary vascular remodeling to in vivo studies and tissue analyses for vasoactive compounds and select growth factors in lungs from patients with PH. Table 3 generally summarizes these findings and again compares the various findings in patients with PH due to lung disease to patients with pulmonary arterial hypertension. A germline genetic mutation in the Bone-morphogenetic protein receptor-2 gene on the short arm of chromosome two has been found among members of 50% to 60% of families with familial PPH. It is inherited in an autosomal dominant fashion with incomplete penetrance [13•,14•] Nevertheless, the phenomenon of genetic anticipation has been seen wherein subsequent affected members present at a younger age and with more severe disease. Surprisingly, 26% of patients with sporadic PPH were also found to have this genetic abnormality [15•]. It will be interesting to see if other patients with pulmonary arterial hypertension or PH due to lung disease have any of these genetic abnormalities. These genetic discoveries offer promise to further elucidate the mecha- nisms of pulmonary vascular remodeling in PPH as well as other pulmonary hypertensive disorders. An imbalance of certain circulating coagulation and tissue factors has been reported in humans, and these aberrancies are felt to contribute to the development of in situ thrombosis in these patients [62] [63] [64] [65] [66] [67] [68] . It is not known whether the abnormalities demonstrated in these studies are primary defects or whether they are acquired secondary to the remodeling process. Increased circulating Thromboxane A2, presumably from platelets and decreased prostacyclin production, was reported in patients with PPH, in patients with other forms of pulmonary arterial hypertension and in a limited number of patients with PH due to lung disease. In contrast, patients with COPD who did not have PH had levels of metabolites of these compounds similar to the levels seen in control individuals [64] . Endothelin is a very potent pulmonary vasoconstrictor and is a weak mitogen or co-mitogen for smooth muscle cells and fibroblasts [53, 54] . [73] . Experimental models have also shown changes in this transporter in response to hypoxia so it may also be important in the pulmonary vascular remodeling changes seen with PH and lung disorders (Table 3) . VEGF is a peptide growth factor that has specific effects on endothelial cells. As such, VEGF receptors are exclusive to endothelial cells and have been used as a marker for this cell type. In contrast to the putative effects of the compounds noted above, VEGF promotes endothelial repair. It is released by platelets at sites of vascular injury via platelet aggregation [77] , and platelet VGEF levels have been reported to be elevated in patients with PH [78] .
Conclusion
PH contributes to the morbidity of many patients with lung disorders and is associated with a worse prognosis; it is mild to moderate in most patients with PH and lung disease, and certain remodeling changes seen in the more severe forms are not demonstrated in these patients. Most changes seen in patients with PH and lung disorders are characteristic of the changes described with chronic hypoxia, and there is the potential for partial reversibility of this process with correction of hypoxemia. Decreased prostacyclin and NO production in the lungs of patients with PH and lung disease have been suggested by certain in vivo and pathologic human studies. Newer inhalational delivery systems may allow for selective replacement, vasodilation, and inhibition of remodeling with these agents [79] [80] [81] [82] . The cascade of mediators and growth factors that are induced by chronic hypoxia and parenchymal lung disease also likely contribute to PH in these patients. New therapies that target some of these defects, such as endothelin receptor antagonists and phosphodiesterase inhibitors, will hopefully be able to provide benefit to patients with PH and lung disorders in the next few years [59] [60] [61] [83] [84] [85] [86] [87] . Other discoveries discussed above will likely provide additional pathways to target novel therapies for patients with PH due to lung disease in the future. 
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